SEC 13F Intelligence

Octagon Capital Advisors LP / VRDN

Octagon Capital Advisors LP’s Viridian Therapeutics Inc Position

Does Octagon Capital Advisors LP own Viridian Therapeutics Inc (VRDN)? Not currently — the last reported position was 450.0K shares worth $6M in Q1 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$6M
Q1 2025
Shares
450.0K
% of Portfolio
+1.17%
Quarters Held
10
position exited

Position History VRDN

Reported value by quarter
Q4 ’22: $24MQ4 ’22Q1 ’23: $30MQ2 ’23: $22MQ2 ’23Q3 ’23: $16MQ4 ’23: $14MQ4 ’23Q1 ’24: $11MQ2 ’24: $8MQ2 ’24Q3 ’24: $20MQ4 ’24: $17MQ4 ’24Q1 ’25: $6Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2025450.0K$6M+1.17%
Q4 2024870.0K$17M+2.74%
Q3 2024870.0K$20M+3.08%
Q2 2024620.0K$8M+1.27%
Q1 2024620.0K$11M+1.30%
Q4 2023620.0K$14M+2.16%
Q3 20231.07M$16M+2.51%
Q2 2023923.0K$22M+3.06%
Q1 20231.19M$30M+4.34%
Q4 2022824.2K$24M+3.75%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of VRDN.